Stock Market & Financial Investment News

News Breaks February 15, 2013 09:03 EDT SGNT Sagent Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Sagent Pharmaceuticals citing greater visibility following the company's Q4 results and raised its price target for shares to $22 from $15. News For SGNT From The Last 14 Days Check below for free stories on SGNT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 6, 2013 08:31 EDT SGNT Sagent Pharmaceuticals to host a conference call Conference Call to discuss the agreement to acquire remaining 50% interest in its joint venture partner, Chengdu Kanghong Pharmaceuticals, as well as 1Q13 earnings, will be held on May 6 at 9 am. Webcast Link 07:12 EDT SGNT Sagent Pharmaceuticals acquires remaining 50% interest in Chinese JV Subscribe for More Information 07:10 EDT SGNT Sagent Pharmaceuticals sees FY13 revenue $220M-$250M, consensus $238.13M Sees FY13 net income $5M-$15M. 07:08 EDT SGNT Sagent Pharmaceuticals reports Q1 EPS 34c, may not compare to consensus (3c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.